We could not find any results for:
Make sure your spelling is correct or try broadening your search.
SciSparc Ltd is a specialty clinical-stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The compa... SciSparc Ltd is a specialty clinical-stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company operates in the single segment of the Development of drugs based on cannabinoid molecules to be approved by an official regulatory authority. Show more
To date, SciSparc has advanced $4.25 million to Automax under the Bridge Loan agreement and amendments thereto TEL AVIV, Israel, Sept. 11, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC...
Pioneering Therapeutic Approach Aims to Enhance Safety and Efficacy in Mental Health and Addiction Treatments TEL AVIV, Israel, Sept. 06, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC...
TEL AVIV, Israel, Aug. 29, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0506 | -14.4200626959 | 0.3509 | 0.4791 | 0.284 | 2856372 | 0.38692534 | CS |
4 | -0.6297 | -67.7096774194 | 0.93 | 1.31 | 0.284 | 3628175 | 0.50207391 | CS |
12 | -2.5897 | -89.6089965398 | 2.89 | 3.63 | 0.284 | 1880827 | 0.66050854 | CS |
26 | -3.7037 | -92.5 | 4.004 | 14.2199 | 0.284 | 2527472 | 3.85056881 | CS |
52 | -181.6997 | -99.835 | 182 | 184.08 | 0.284 | 1610933 | 15.68174451 | CS |
156 | -181.6997 | -99.835 | 182 | 184.08 | 0.284 | 1610933 | 15.68174451 | CS |
260 | 0 | 0 | 0 | 0.3362 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions